WellStar Cobb Hospital

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Melanoma2 trials
• Metastatic breast cancer2 trials
• Multiple myeloma2 trials
• Prostate cancer2 trials
• Colorectal cancer1 trial
• Diffuse large B-cell lymphoma1 trial
• Endometrial cancer1 trial
• Follicular lymphoma1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Ovarian cancer1 trial
• and 2 more

Phase

• Phase 312 trials
• Phase 23 trials
• Phase 2/31 trial

Status

• Active, not recruiting8 trials
• Completed7 trials
• Recruiting1 trial

Lead sponsor

• National Cancer Institute (NCI)9 trials
• NRG Oncology3 trials
• SWOG Cancer Research Network2 trials
• ECOG-ACRIN Cancer Research Group1 trial
• Pfizer1 trial

Running trials

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· NRG Oncology· Source

  Contact: Mark P. McLaughlin (principal investigator)

• Active, not recruiting

  Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

  NCT05053152· Phase 2· NRG Oncology· Source

• Active, not recruiting

  Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

  NCT04821622· Phase 3· Pfizer· Source

• Active, not recruiting

  Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

  NCT02502266· Phase 2/3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT00602641· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Closed trials

• Completed

  S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

  NCT01359592· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

  NCT00006721· Phase 3· SWOG Cancer Research Network· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source